Industry News
Early success for Biosignal's anti-bacterial contact lenses
Biosignal (ASX:BOS) and the Institute for Eye Research Ltd (IER) have reported interim results from recent in vitro trials of contact lenses with permanently attached furanones. [ + ]
Alchemia gets results with anti-cancer compound
Alchemia (ASX: ACL) will commence the preclinical studies necessary to take its lead anti-cancer compound into human clinical trials after positive results from studies in an animal model of lung cancer. [ + ]
GTG shares soar on back of Applera lawsuit news
The share price of Genetic Technologies (ASX: GTG) has risen over 50 per cent since the judge in GTG's lawsuit against Applera ruled largely in the company's favour during the Markman hearing last Thursday. [ + ]
Osteoarthritis measuring tool
Researchers from Monash University's Department of Epidemiology and Preventive Medicine are claiming to have revolutionised knee scans with the development of technology that harnesses the power of magnetic resonance imaging (MRI).
[ + ]Why does cloning create abnormalities?
Significant abnormalities observed in cloned mice help reinforce the need to continue to avoid the reproductive cloning of humans, claims Dr Takumi Takeuchi, from Cornell University.
[ + ]The key to the mammalian genome
Ongoing research into how the mammalian genome works could lead to major advances in livestock production, according to CSIRO Livestock Industries' researcher, Dr Brian Dalrymple.
[ + ]PM award for Monash researcher
Monash researcher Dr Jamie Rossjohn has received a Prime Minister's award for his contribution to science.
[ + ]Consultant wins ACT Business Woman of the Year award
Biotech consultant Dr Lyndal Thorburn has been named the 2004 Telstra Business Woman of the Year for the ACT. [ + ]
Isis antisense drug delays tumour growth
Shares of California-based Isis Pharmaceuticals rose as much as 13 per cent on Thursday after it said its experimental anti-cancer compound significantly delayed tumour growth and increased the rate of malignant cell death in cell and animal models. [ + ]
New NZ fund set up for agbiotech investment
A New Zealand-based venture capital fund of between NZ$75-100 million (AUD$70-94.5 million), with a focus on agricultural biotech has been established by the venture capital arm of the NZ government and private collaborators Direct Capital and crown research institute AgResearch. [ + ]
Avastra investigates using Bioweld for drug deliery
NSW biomaterials company Avastra (ASX: AVS) is investigating the potential of its BioWeld technology -- which uses a protein solder activated by laser light to fuse together blood vessels -- as a drug delivery mechanism. [ + ]
Fumigant replaces damaging gas
CSIRO and the global industrial gas company the BOC Group have signed a deal to deliver to the international market a new environmentally-safe fumigant for treating soil, insect pests, weeds and diseases.
[ + ]Hep B mutation analysis platform developed by Vic disease lab
The Victorian Infectious Diseases Reference Laboratory (VIDRL) has developed a platform which analyses mutations in hepatitis B virus strains carried by patients with chronic disease, and then recommends treatments based on the virus resistance profile. [ + ]
GTG price jumps on Applera lawsuit news
The share price of Genetic Technologies (ASX:GTG) jumped 25 per cent today on heavy trading after the company announced that the judge in GTG's lawsuit against Applera had ruled largely in the company's favour during the Markman hearing, in which the court rules on the precise meanings of certain disputed technical terms within GTG's patent claims. [ + ]
Biota launches share purchase plan
Biota (ASX:BTA) has launched a share purchase plan, which could raise almost AUD$15 million for the company if fully subscribed. [ + ]